BR0317433A - Derivados bicìclicos para o tratamento do crescimento celular anormal - Google Patents

Derivados bicìclicos para o tratamento do crescimento celular anormal

Info

Publication number
BR0317433A
BR0317433A BR0317433-6A BR0317433A BR0317433A BR 0317433 A BR0317433 A BR 0317433A BR 0317433 A BR0317433 A BR 0317433A BR 0317433 A BR0317433 A BR 0317433A
Authority
BR
Brazil
Prior art keywords
formula
cell growth
abnormal cell
vou
treatment
Prior art date
Application number
BR0317433-6A
Other languages
English (en)
Inventor
John Charles Kath
Zhengyu Liu
Maria Steflik Brown
Steven Mark Winter
Susan Jane Truesdell
Ruby Anthea Szewc
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0317433A publication Critical patent/BR0317433A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS BICìCLICOS PARA O TRATAMENTO DO CRESCIMENTO CELULAR ANORMAL". A invenção relaciona-se com compostos de fórmula <um>1<vou> e com os seus sais, pró-fármacos e solvatos farmaceuticamente aceitáveis, em que R¬ 1¬, R¬ 2¬. R¬ 3¬ e R¬ 5¬ são como aqui definidos, e em que o composto de fórmula <um>1<vou>: opcionalmente ainda compreende um substituinte hidroxilo ou um ácido O-glucurónico. A invenção também se relaciona com métodos de tratamento do crescimento celular anormal em mamíferos por administração de compostos de fórmula <um>1<vou> e com composições farmacêuticas para o tratamento destas doenças que contêm os compostos de fórmula <um>1<vou>. A invenção também se relaciona com métodos de preparação de compostos de fórmula <um>1<vou>.
BR0317433-6A 2002-12-18 2003-12-08 Derivados bicìclicos para o tratamento do crescimento celular anormal BR0317433A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43448602P 2002-12-18 2002-12-18
PCT/IB2003/005826 WO2004054585A1 (en) 2002-12-18 2003-12-08 4-anilino quinazoline derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
BR0317433A true BR0317433A (pt) 2005-11-16

Family

ID=32595280

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317433-6A BR0317433A (pt) 2002-12-18 2003-12-08 Derivados bicìclicos para o tratamento do crescimento celular anormal

Country Status (20)

Country Link
US (1) US20040254204A1 (pt)
EP (1) EP1575592A1 (pt)
JP (1) JP2006513179A (pt)
KR (1) KR20050085749A (pt)
CN (1) CN1729001A (pt)
AR (1) AR042480A1 (pt)
AU (1) AU2003303045A1 (pt)
BR (1) BR0317433A (pt)
CA (1) CA2510323A1 (pt)
GT (1) GT200300286A (pt)
MX (1) MXPA05006335A (pt)
NL (1) NL1025044C2 (pt)
NO (1) NO20053483L (pt)
PA (1) PA8592801A1 (pt)
PE (1) PE20040905A1 (pt)
PL (1) PL377686A1 (pt)
RU (1) RU2005119172A (pt)
TW (1) TW200424190A (pt)
WO (1) WO2004054585A1 (pt)
ZA (1) ZA200504147B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
EP1658080A1 (en) * 2003-08-18 2006-05-24 Pfizer Products Inc. Dosing schedule for a erbb2 anticancer agents
ATE532782T1 (de) 2003-09-26 2011-11-15 Exelixis Inc C-met-modulatoren und anwendungsverfahren
CA2610491A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Bicyclic derivatives for the treatment of abnormal cell growth
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
EA019959B1 (ru) 2009-01-16 2014-07-30 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее кристаллические формы для лечения рака
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
DK2621481T4 (da) 2010-09-27 2023-01-09 Exelixis Inc Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711783A1 (en) * 1994-11-08 1996-05-15 Glaxo, S.A. Antifungal Sordarin derivatives
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EP1218354B1 (en) * 1999-09-21 2009-11-18 AstraZeneca AB Quinazoline derivatives and their use as pharmaceuticals
IL150430A0 (en) * 2000-01-18 2002-12-01 Nereus Pharmaceuticals Inc Cell division inhibitors and process for producing the same
NZ522568A (en) * 2000-06-22 2004-12-24 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
JP4220388B2 (ja) * 2001-11-30 2009-02-04 ファイザー・プロダクツ・インク 異常な細胞増殖を処置するための置換された二環式誘導体の製造方法
AU2002339687A1 (en) * 2001-12-12 2003-06-23 Pfizer Products Inc. Quinazoline derivatives for the treatement of abnormal cell growth
JP4202926B2 (ja) * 2001-12-12 2008-12-24 ファイザー・プロダクツ・インク Ｅ−２−メトキシ−ｎ−（３−（４−（３−メチル−ピリジン−３−イロキシ）−フェニルアミノ）−キナゾリン−６−イル）−アリル）−アセトアミドの塩形態、その製造および癌に対するその使用

Also Published As

Publication number Publication date
CA2510323A1 (en) 2004-07-01
US20040254204A1 (en) 2004-12-16
AR042480A1 (es) 2005-06-22
GT200300286A (es) 2004-08-13
PE20040905A1 (es) 2005-01-18
EP1575592A1 (en) 2005-09-21
NO20053483L (no) 2005-09-19
NL1025044C2 (nl) 2005-02-15
AU2003303045A1 (en) 2004-07-09
RU2005119172A (ru) 2006-01-20
NO20053483D0 (no) 2005-07-18
ZA200504147B (en) 2006-07-26
KR20050085749A (ko) 2005-08-29
CN1729001A (zh) 2006-02-01
WO2004054585A1 (en) 2004-07-01
NL1025044A1 (nl) 2004-06-21
PA8592801A1 (es) 2004-07-26
JP2006513179A (ja) 2006-04-20
PL377686A1 (pl) 2006-02-06
TW200424190A (en) 2004-11-16
MXPA05006335A (es) 2005-08-26

Similar Documents

Publication Publication Date Title
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BR0008202A (pt) Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
BR0111548A (pt) Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
UA89123C2 (ru) Производные пиримидина для лечения абнормального роста клеток
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
BR9913138A (pt) Derivados de quinolin-2-ona substituìdos com alquinila úteis como agentes contra o câncer
BR0317524A (pt) Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
WO2006018182A8 (en) Combinations for the treatment of diseases involving cell proliferation
NO20061657L (no) Pyrolderivater med antibakteriell aktivitet
BR0015911A (pt) Derivados de benzoimidazole úteis como agentes antiproliferativos
SE0202462D0 (sv) Novel use
AR050045A1 (es) Derivados de pirrolo[3,4-c]pirazol activos como inhibidores de quinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
NO20053483L (no) 4-Anilinokinazolinderivater for behandling av unormal cellevekst
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0406717A (pt) Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
BR0215277A (pt) Dicetopiperazinas substituìdas como antagonistas da oxitocina
BR9908125A (pt) Composto, composto dimérico, composição farmacêutica, uso do composto, processo compreendendo inibir células de câncer, e, processo terapêutico
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.